Top-Line Human Clinical Study Results Demonstrate Safety and Preliminary Effectiveness of Cohera Medical's TissuGlu(R)

By Cohera Medical Inc., PRNE
Tuesday, May 4, 2010

Positive Results for Surgical Adhesive in Abdominoplasty (Tummy Tuck) Procedures Move Product Toward CE Mark Application in Europe and Clinical Study in U.S. This Year

PITTSBURGH, May 5, 2010 - Cohera Medical, Inc.(R) today announced that top-line clinical study
results demonstrate the safety and preliminary effectiveness of the company's
lead surgical adhesive product, TissuGlu(R).

The prospective, open-label, randomized study involving 40 patients at
three sites in Germany met its primary endpoints of safety and preliminary
effectiveness related to time to drain removal and secondary endpoints of
associated wound healing complications, cumulative wound drainage, number of
additional procedures and visits, and improved quality of life. In the trial,
investigators compared standard wound closure techniques used in
abdominoplasty surgeries, or "tummy tuck," to standard wound closure
techniques plus the application of TissuGlu. The purpose of the study was to
determine TissuGlu's effect on wound drainage and associated complications in
the surgeries.

"We are pleased that the top-line clinical trial results demonstrate both
the safety and preliminary effectiveness of TissuGlu," said Klaus Walgenbach,
M.D., Ph.D., of the Universitatsklinikum Bonn and the principal investigator
for the study. "The product has the potential to change the way plastic
surgeons address the wound drainage challenges of abdominoplasty procedures.
We look forward to presenting detailed study results at an upcoming medical
conference as well as submitting them for publication."

The positive results from the first-in-man study of Cohera's surgical
adhesive in abdominoplasty procedures move the product toward CE Mark
application in Europe and a larger clinical study in the U.S. this year.

"We are moving quickly to address a significant unmet medical need while
helping plastic surgeons to improve the overall care of their patients," said
Patrick Daly, president and chief executive officer of Cohera Medical. "The
positive study results add to the extensive preclinical data that show the
safety and effectiveness of TissuGlu. We envision the TissuGlu market
opportunity in plastic surgery to encompass applications beyond tummy tuck,
such as breast reconstruction and body contouring. This is a large
opportunity that can exceed US$700 million world wide."

Currently, patients who undergo abdominoplasty require the insertion of
drains to remove fluids that accumulate under the skin at the surgical site.
In some cases, drainage is inadequate, and the excess fluid accumulation
called seroma requires an additional procedure for removal. TissuGlu adheres
the tissue flaps created during the procedure to reduce fluid accumulation,
and, ultimately, the duration of use of the surgical drains. With the use of
TissuGlu, patients may experience a significant reduction of fluid
accumulation and a more comfortable recovery, which may lead to a quicker
return to normal activity.

About Cohera Medical

Cohera Medical, Inc. is a Pittsburgh-based company that is developing a
revolutionary line of surgical adhesives. Cohera Medical's products are based
on a unique chemical design that is purely synthetic, easy to use,
biocompatible and fully resorbable. The company's lead product in
development, TissuGlu, is an adhesive for plastic surgery procedures.
TissuGlu adheres flaps of tissue after surgical procedures, eliminating the
spaces where fluid accumulates and reducing wound drainage. Cohera Medical is
also developing surgical adhesives targeting mesh fixation, small bone
fixation and other plastic surgery indications that will fill similar market
needs in plastic, orthopedics and general surgery. For more information,
visit TissuGlu and the other Cohera products are
currently indicated for investigational use only and have not yet been
approved for medical use by the Food and Drug Administration (FDA) in the
U.S. or in any other market.

Certain statements made throughout this news release that are not
historical facts contain forward-looking statements regarding the Company's
future plans, objectives and expected performance. Any such forward-looking
statements are based on assumptions that the Company believes are reasonable,
but are subject to a wide range of risks and uncertainties and, therefore,
there can be no assurance that actual results may not differ materially from
those expressed or implied by such forward-looking statements.

Media Contacts: David Schull, david.schull at or Martina Schwarzkopf, Ph.D., martina.schwarzkopf at, both of Russo Partners, +1-212-845-4271 or Patrick Daly, Cohera Medical, +1-412-231-1500, ext. 101, pdaly at; or Clinical Trial Contact: Chad Coberly, Cohera Medical, +1-412-246-2563, ccoberly at

will not be displayed